Currently, the HMA/Ven doublet is an established standard of care for newly diagnosed patients with FLT3 unfit for intensive chemotherapy, but relapses inevitably occur despite high initial CR rates (comparable between FLT3mut and FLT3wt), with FLT3-ITD AML having shorter remissions and lower overall survival rates [45,46]. This evidence concerns the gene FLT3 and acute myeloid leukemia.